Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KJ103 in anti-Glomerular Basement Membrane Disease
NCT06607016Phase 2Active, not recruiting
- Sponsor
- Shanghai Bao Pharmaceuticals Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Dec 2025
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ricefidase in anti-glomerular basement membrane disease, sponsored by Shanghai Bao Pharmaceuticals Co., Ltd.. Started Oct 2024; status: active, not recruiting.
02
Drugs
ricefidase
03
Conditions
anti-glomerular basement membrane disease
Beyond the preview
Go deeper on NCT06607016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06607016.